Definium Therapeutics, Inc.
DFTX
$22.01
$0.854.02%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 101.50% | 31.34% | 93.20% | 13.05% | -16.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.15% | 46.57% | 84.21% | 67.24% | 44.83% |
| Operating Income | -84.15% | -46.57% | -84.21% | -67.24% | -44.83% |
| Income Before Tax | -230.21% | -45.18% | -391.56% | -630.17% | 57.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -230.21% | -45.18% | -391.56% | -630.17% | 57.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -230.21% | -45.18% | -391.56% | -630.17% | 57.08% |
| EBIT | -84.15% | -46.57% | -84.21% | -67.24% | -44.83% |
| EBITDA | -- | -46.54% | -84.18% | -67.21% | -48.32% |
| EPS Basic | -158.18% | -20.66% | -346.01% | -515.23% | 75.85% |
| Normalized Basic EPS | -158.25% | -20.64% | -345.81% | -328.77% | 75.86% |
| EPS Diluted | -103.79% | -20.51% | -185.11% | -95.40% | 69.44% |
| Normalized Diluted EPS | -164.26% | -20.64% | -359.19% | -349.07% | 76.41% |
| Average Basic Shares Outstanding | 27.89% | 20.34% | 10.24% | 18.68% | 77.74% |
| Average Diluted Shares Outstanding | 24.92% | 20.34% | 7.04% | 13.34% | 81.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |